In conclusion, wogonoside attenuates colitis-related tumor development in mice by inhibiting NF-κB activation through the PI3K/AKT pathway and inhibits progression of human CRC in an inflammatory microenvironment. The gene discussed is NFKB1; the disease is colitis.